Shares in this article
Overland ADCT BioPharma, a joint venture formed by Overland Pharmaceuticals and ADC Therapeutics SA (NYSE: ADCT), today announced the appointment of Eric Koo, B.Sc., MBA as Chief Executive Officer. Eric Koo brings over 25 years of pharmaceutical industry leadership experience to Overland ADCT BioPharma and has a proven track record of drug approval processes and product launches in Asia.
This press release contains multimedia content. View the full announcement here: https://www.businesswire.com/news/home/20210406006191/en/
Eric Koo, B.Sc., MBA (Photo: Business Wire)
“Overland ADCT BioPharma now has a promising opportunity to bridge the clinical gap between the US, Europe and Asia with the wider reach of innovative cancer drugs such as antibody-drug conjugates,” said Eric Koo, B.Sc., MBA. “The The position of Chief Executive Officer is a fascinating new challenge and I look forward to working closely with both teams at Overland Pharmaceuticals and ADC Therapeutics to develop and commercialize the product pipeline in Grochina and Singapore.
Eric Koo most recently served as Vice President, Head of Oncology Business Unit at Takeda China, where he focused on multiple myeloma and lymphoma. Prior to his position at Takeda China, Eric Koo was Director, Oncology Business Unit and Director, Market Access, External Affairs & Key Account Management at Merck, Sharp and Dome (MSD) Taiwan. An earlier part of his career was devoted to his duties as Regional Marketing Director for APAC and Specialty Care BU Head, Malaysia / Singapore at Bayer APAC. Eric Koo started his pharmaceutical career at Pfizer and spent 16 years in various sales, product management and marketing positions at both Pfizer Taiwan and Pfizer Emerging Market Asia & China, including a six-year tenure as China / APAC Regional Marketing Director for Oncology.
Eric Koo received his B.Sc. in Pharmacy from Taipei Medical University and his MBA from the University of North Carolina at Charlotte, Belk College of Business.
“Eric Koo arrives at a significant time in Overland’s joint venture development as Lonca’s US PDUFA date is approaching this May,” said Chris Martin, CEO of ADC Therapeutics. “We are delighted to have such a highly qualified to welcome distinguished and visionary leaders such as Eric Koo to lead Overland ADCT BioPharma in its pursuit of the development and commercialization of Lonca and other ADCs for hard-to-treat hematologic cancers and solid tumor indications in Greater China and Singapore.
“Given Eric Koo’s impressive experience and track record in expanding access to life-changing cancer therapies in China and beyond, I look with great confidence in the ability of Overland ADCT Biopharma to achieve its goal and patients in Asia and around the world To provide innovative AWK drugs, said Ed Zhang, MBA, co-founder of Overland Pharmaceuticals. “Since its launch in December 2020, Overland ADCT BioPharma has submitted two clinical trial proposals to evaluate Lonca. This underlines the scale, speed and consistent implementation of its strategic business model. We look forward to further developing the Overland ADCT BioPharma product pipeline under the leadership of Eric Koo.
Overland ADCT BioPharma’s lead program is Lonca, a humanized monoclonal antibody-drug conjugate (AWK) targeting human CD19 coupled to pyrrolobenzodiazepine (PBD) dimer cytotoxin. Lonca was evaluated by ADC Therapeutics in a pivotal Phase II clinical trial in patients with relapsed or refractory DLBCL and is currently in two ongoing studies, a Phase I / II study in combination with ibrutinib in patients with relapsed or refractory DLBCL Mantle cell lymphoma and a confirmatory phase III study in combination with rituximab in patients with relapsed or refractory DLBCL. The Overland ADCT BioPharma portfolio also includes ADCT-602, the CD22-targeting drug candidate currently in clinical development in a Phase I / II clinical trial in patients with relapsed or refractory acute lymphoblastic leukemia, and the AXL-targeting one ADCT-601, currently in Phase I clinical trials in patients with selected advanced solid tumors. ADCT-901, targeting KAAG1, is a drug in preclinical development for the treatment of advanced solid tumors with high unmet medical need.
About Overland ADCT BioPharma
Overland ADCT BioPharma a joint venture that emerged from Overland Pharmaceuticals and ADC Therapeutics SA is developing and commercializing four AWK product candidates (antibody-drug conjugates) from ADC Therapeutics for difficult-to-treat hmatological and solid tumors Loncastuximab-Tesirin (Lonca), ADCT- 601, ADCT-602 and ADCT-901 in Greater China and Singapore.
about ADC Therapeutics
ADC Therapeutics SA (NYSE: ADCT) is a late-stage clinical research biotechnology company focused on oncology and a pioneer in the development and commercialization of high-potency and targeted antibody-drug conjugates (AWC) for patients with hematological malignancies and solid tumors. The company is developing a comprehensive clinical pipeline based on decades of experience in the field and strategic target selection, as well as using next-generation proprietary pyrrolobenzodiazepine (PBD) technology. By applying as a biopharmaceutical product (Biologics License Application) for its lead product candidate Loncastuximab-Tesirine (Lonca, formerly ADCT-402) for the treatment of relapsed or refractory, diffuse large-cell B-cell lymphoma, the US Food and Drug Administration granted Pharmaceuticals (FDA) and set May 21, 2021 as the target date under the Prescription Drug User Fee Act (PDUFA). Camidanlumab-tesirine (Cami, formerly ADCT-301), the company’s second lead product candidate, is being evaluated in a pivotal Phase II clinical trial with 117 patients for the treatment of patients with relapsed or refractory Hodgkin lymphoma (HL).
ADC Therapeutics is based in Lausanne (Biople), Switzerland, and has operations in London, the San Francisco Bay Area and New Jersey. For more information, please visit https://adctherapeutics.com/ and follow the company on Twitter and LinkedIn.
about Overland Pharmaceuticals
Overland Pharmaceuticals is building a fully integrated biopharmaceutical company dedicated to delivering innovative medicines to underserved patients in Asia and around the world. By making optimal use of our resources, our global network and our local expertise in the entire biopharmaceutical ecosystem in Asia, Overland is developing a portfolio of differentiated therapeutic candidates in a few carefully selected therapeutic areas. Through formative partnerships, Overland will advance the development and commercialization of the most promising approaches in medicine. Www.overlandpharma.com
Forward-Looking Statements from ADC Therapeutics
This press release contains statements that constitute forward-looking statements. All statements in this press release that are not historical facts, including statements about our future operating results and financial condition, our business strategy, our product candidates, our research pipeline, ongoing and planned preclinical and clinical studies, regulatory filings and approvals, are accepted Planned marketing activities, research and development costs, the schedule and the probability of success, as well as the plans and goals of management for future operations, are forward-looking statements. Forward-looking statements are based on the assessments and assumptions of our management as well as on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may vary due to various factors, including those set out in our U.S. Securities and Exchange Commission filings described may differ materially from the results expressed or implied in the forward-looking statements. There can be no assurance that such future results will be achieved. The forward-looking statements contained in this document speak only as of the date of this press release. We expressly disclaim any obligation or undertaking to update the forward-looking statements contained in this press release to reflect changes in our expectations or changes in the events, conditions or circumstances on which these statements are based, unless required by applicable law . No representations or warranties are made (either expressed or implied) as to the accuracy of such forward-looking statements.
The source language in which the original text is published is the official and authorized version. Translations are included for better understanding. Only the language version that was originally published is legally valid. You should therefore compare translations with the original language version of the publication.